<SEC-DOCUMENT>0001178913-20-002843.txt : 20201019
<SEC-HEADER>0001178913-20-002843.hdr.sgml : 20201019
<ACCEPTANCE-DATETIME>20201019073012
ACCESSION NUMBER:		0001178913-20-002843
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20201019
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201019
DATE AS OF CHANGE:		20201019

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ReWalk Robotics Ltd.
		CENTRAL INDEX KEY:			0001607962
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36612
		FILM NUMBER:		201245234

	BUSINESS ADDRESS:	
		STREET 1:		3 HATNUFA ST.
		STREET 2:		FLOOR 6
		CITY:			YOKNEAM ILIT
		STATE:			L3
		ZIP:			2069203
		BUSINESS PHONE:		97249590123

	MAIL ADDRESS:	
		STREET 1:		3 HATNUFA ST.
		STREET 2:		FLOOR 6
		CITY:			YOKNEAM ILIT
		STATE:			L3
		ZIP:			2069203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Argo Medical Technologies Ltd.
		DATE OF NAME CHANGE:	20140513
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>zk2025001.htm
<DESCRIPTION>8-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED STATES</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="text-align: center; text-indent: 36pt; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM 8-K</div>
      <div style="text-align: center; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">CURRENT REPORT</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Date of Report (Date of earliest event reported): <u> October 14, 2020</u></div>
      <div style="text-align: justify; line-height: 1.25;">&#160;
        <table cellspacing="0" cellpadding="0" border="0" id="z64e6832b762849b38501d810c9a8bf95" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 100%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">
                  <div style="text-align: center; line-height: 1.25;">ReWalk Robotics Ltd.</div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; line-height: 1.25;">(Exact name of registrant as specified in its charter)</div>
              </td>
            </tr>

        </table>
      </div>
      &#160;&#160;
      <table cellspacing="0" cellpadding="0" border="0" id="zb6caa004b815415a8cb9c46c9139a475" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25;">Israel</div>
            </td>
            <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25;">001-36612</div>
            </td>
            <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25;">Not applicable</div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">(State or Other Jurisdiction of Incorporation)</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">(Commission File Number)</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">(IRS Employer Identification No.)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25;">3 Hatnufa St., Floor 6, Yokneam Ilit, Israel</div>
            </td>
            <td nowrap="nowrap" style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; line-height: 1.25;">2069203</div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25;">(Zip Code)</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Registrant&#8217;s telephone number, including area code: <u>+972.4.959.0123</u></div>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0c189356a6d549d28207980582c4fc30" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25;">Not applicable</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center; line-height: 1.25;">(Former name or former address, if changed since last report)</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Securities registered pursuant to Section 12(b) of the Exchange Act:</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z00a958ee80a34e17bb606632f9008f71" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 32.01%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Title of each class</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Trading symbol</div>
            </td>
            <td style="width: 2%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 32%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 1.25; font-weight: bold;">Name of each exchange on which registered</div>
            </td>
          </tr>
          <tr>
            <td style="width: 32.01%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">Ordinary shares, par value NIS 0.25</div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 32%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">RWLK</div>
            </td>
            <td style="width: 2%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: justify; line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 32%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center; line-height: 1.25;">Nasdaq Capital Market</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 18pt; line-height: 1.25;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="font-style: italic;">see </font>General Instruction A.2. below):</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb1198575d4fb488b9c9ae7489fd4a0fc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3.85%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.85%; vertical-align: top;"> &#9744; </td>
            <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z57c312614f3946979f0df01b32bb9585" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3.85%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.85%; vertical-align: top;"> &#9744; </td>
            <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6a94376257784d3f9f74ab3c1f9cae8f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3.85%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.85%; vertical-align: top;"> &#9744; </td>
            <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb918a3d1f0d94ef89517703e87be4bf3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3.85%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 3.85%; vertical-align: top;"> &#9744; </td>
            <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>
          </tr>

      </table>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
        (&#167;240.12b-2 of this chapter).</div>
      <div style="line-height: 1.25;">&#160;&#160;</div>
      <div style="line-height: 1.25;">Emerging growth company &#9744;</div>
      <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section 13(a) of the Exchange Act. &#9744;</div>
      <div style="line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Item&#160;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">(d) Appointment of Director.</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 27.5pt; line-height: 1.25;">On October 14, 2020, the board of directors (the &#8220;Board&#8221;) of ReWalk Robotics Ltd. (the &#8220;Company,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) appointed Ms. Randel E. Richner as a Class II Director of the Company, with such
        appointment to take effect on November 1, 2020. Ms. Richner was appointed to fill a vacancy on the Board. Ms. Richner has not yet been appointed to any committees of the Board.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 27.5pt; line-height: 1.25;">Ms. Richner, 65, has over thirty years&#8217; experience in health policy, reimbursement, and economics. From 2013 to 2015, Ms. Richner served as Executive Vice President of Intralign Health, LLC. From
        2006 to 2012, she was President and Founder of Neocure Group, data analytics, health economics and reimbursement strategic services, acquired by Intralign Health, LLC, 2013. From 1997 to 2006, Ms. Richner was Vice President of Global Government
        Affairs and Reimbursement, Boston Scientific Corporation.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 27.5pt; line-height: 1.25;">
        <div style="text-indent: 27.5pt; line-height: 1.25;">Ms. Richner has engaged with U.S. Congress and CMS, appointed as first industry representative, Executive
          Committee (EC) Medicare Coverage Advisory Committee (MCAC). Presently, she is&#160;on the
          Executive Dean&#8217;s Advisory Board, University of Michigan&#8217;s School of Public Health, Executive Board MichBio, Chairperson, Diversity Council.&#160; Mr. Richner has served
          on multiple boards including MassMedic (founding Women in MedTech), Executive
          Advisory Board Center for Evaluation Value, Risk Tufts New England Medical Center, International Society of Pharmacoeconomics and Research (ISPOR), founding the U.S.
          Medical Device Council. She&#8217;s an invited executive lecturer Dartmouth, Tuck School of Business, University of Michigan School of Engineering and School of Public Health.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>She has a Master of Public Health in Health Policy and
          Administration and a Bachelor of Science in Nursing from University of Michigan.</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-indent: 27.5pt; line-height: 1.25;">As compensation for her services as director, Ms. Richner will be entitled to standard compensation available to non-employee directors of the Company as disclosed under &#8220;Director Compensation&#8221; in
        the Company&#8217;s definitive proxy statement on Schedule 14A, filed with the SEC on May 12, 2020. Additionally, in connection with her appointment, Ms. Richner has entered into the Company&#8217;s standard form of indemnification agreement and will receive
        coverage under the Company&#8217;s directors&#8217; and officers&#8217; liability insurance policy. Other than with respect to the above-described arrangements, there are no transactions in which Ms. Richner has an interest requiring disclosure under Item 404(a) of
        Regulation S-K, and Ms. Richner does not have any family relationship with any director or executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Item 7.01 Regulation FD Disclosure.</div>
      <div style="text-indent: 27.5pt; line-height: 1.25;">&#160;</div>
      <div style="text-indent: 27.5pt; line-height: 1.25;">On October 19, 2020, the Company issued a press release reporting Ms. Richner&#8217;s appointment as a director of the Board. A copy of the press release is attached hereto as Exhibit 99.1. The
        information in this Item&#160;7.01, including Exhibit 99.1, is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by
        reference into the filings of the Company under the Securities Act of 1933, as amended, regardless of any general incorporation language in those filings.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Item 9.01 Financial Statements and Exhibits.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic;">(d) Exhibits.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" id="z191b7e8cb03c4e7b8f9d1408bb1db1c8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 5.04%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_99-1.htm">99.1</a></div>
            </td>
            <td style="width: 94.96%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_99-1.htm">Press Release of ReWalk Robotics Ltd., dated
                  October 19, 2020.</a></div>
            </td>
          </tr>

      </table>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">SIGNATURES</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>
      <div style="text-indent: 27.5pt; line-height: 1.25;">&#160;&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z11c404062c6647d8aeb36516357dd1a2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="vertical-align: middle;" colspan="2">
              <div style="line-height: 1.25; font-weight: bold;">ReWalk Robotics Ltd.</div>
            </td>
            <td style="width: 23%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="vertical-align: middle;" colspan="2">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 23%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: middle; padding-bottom: 2px;">
              <div style="line-height: 1.25;">By:&#160;</div>
            </td>
            <td style="width: 23%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">/s/ Ori Gon&#160;&#160;</div>
            </td>
            <td style="width: 23%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: middle;">
              <div style="line-height: 1.25;">Name:&#160;&#160;</div>
              <div style="line-height: 1.25;">Title:</div>
            </td>
            <td style="width: 23%; vertical-align: top;">
              <div style="line-height: 1.25;">Ori Gon</div>
              <div style="line-height: 1.25;">Chief Financial Officer</div>
            </td>
            <td style="width: 23%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div style="text-indent: 27.5pt; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">Dated: October 19, 2020</div>
      <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
    </div>
    <div> <br>
    </div>
  </div>
  <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"> <u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
    </div>
    <div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">ReWalk Robotics announces the Appointment of Randel E. Richner, BSN, MPH to its Board of Directors</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Ms. Richner is an experienced public health policy professional with over 30 years of experience in </div>
      <div style="text-align: center; line-height: 1.25; font-style: italic;">Medical Devices, Reimbursement Strategy and Health Care Policy</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">Marlborough MA / Yokneam Ilit Israel /
          Berlin Germany</font> &#8211; ReWalk Robotics. Ltd. (NASDAQ: RWLK) (&#8220;ReWalk&#8221; or the &#8220;Company&#8221;) announced today that the Company has approved the appointment of Randel Richner to the Board of Directors, effective November 1, 2020.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Ms. Richner&#8217;s&#160; extensive history experience in health policy, reimbursement, economics and data analytics includes serving as the
        industry representative on the Centers for Medicare &amp; Medicaid Services&#8217; (&#8220;CMS&#8221;) Medicare Coverage Advisory Committee; service on the Executive Dean&#8217;s Advisory Board at the University of Michigan&#8217;s School of Public Health; establishing the
        global reimbursement and economics function at Boston Scientific as that organization&#8217;s&#160; Vice President of Global Government Affairs and Reimbursement and in founding Neocure, a firm that advised industry on health care policy.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Jeff Dykan, Chairman of ReWalk Robotics states, &#8220;As ReWalk advances its commercialization pathway, Randel has an ideal combination of
        operating industry knowledge and reimbursement policy establishment. Her decision to accept an appointment to our Board will benefit the entire industry with her participation in strategic decisions and in helping guide government policy for
        exoskeletons.&#8221;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Ms. Richner received a Master of Public Health in Health Policy and Administration and a Bachelor of Science in Nursing from the
        University of Michigan in Ann Arbor, Michigan.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">&#160;&#8220;Throughout my career, I have sought to enable access to breakthrough technologies as an important element of public health policy.
        Providing guidance with the ReWalk Board for business strategies that allow individuals to walk again matches my goals in advancing health options for the disabled community,&#8221; said Ms. Richner.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">For more information, please visit <u>www.rewalk.com</u>.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;"><u>About&#160;ReWalk Robotics Ltd.</u></font><br>
        <br>
        ReWalk Robotics Ltd.&#160;develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk's mission is to fundamentally change the quality of life
        for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the United States,&#160;Israel&#160;and&#160;Germany. For more information on the ReWalk systems,
        please visit&#160;<u>www.rewalk.com</u>.<br>
        <br>
        ReWalk&#174; is a registered trademark of ReWalk Robotics Ltd.&#160;in&#160;Israel and&#160;the United States.<br>
        <br>
        ReStore&#174; is a registered trademark of&#160;ReWalk Robotics Ltd.&#160;in&#160;Europe&#160;and an allowed trademark in&#160;the&#160;United States.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">Forward-Looking Statements</font><br>
        <br>
        In addition to historical information, this press release contains forward-looking statements within the meaning of the&#160;U.S.&#160;Private Securities Litigation Reform
          Act of 1995, Section 27A of the&#160;U.S.&#160;Securities Act of 1933, and Section 21E of the&#160;U.S.&#160;Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and other statements that are
          not statements of historical fact and, in some cases, may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will,"
          "should," "would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are
          difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk's
          management's conclusion, and its independent registered public accounting firm's statement in its opinion relating to its consolidated financial statements for the fiscal year ended&#160;December 31, 2019, that there is a substantial doubt as to the
          Company's ability to continue as a going concern; the current COVID-19 pandemic has adversely affected and may continue to affect adversely&#160; business and results of operations; ReWalk's ability to have sufficient funds to meet certain future
          capital requirements, which could impair the Company's efforts to develop and commercialize existing and new products; ReWalk's ability to maintain compliance with the continued listing requirements of the Nasdaq Capital Market and the risk that
          its ordinary shares will be delisted if it cannot do so; ReWalk's ability to establish a pathway to commercialize its products in&#160;China; ReWalk's ability to maintain and grow its reputation and the market acceptance of its products; ReWalk's
          ability to achieve reimbursement from third-party payors for its products; ReWalk's limited operating history and its ability to leverage its sales, marketing and training infrastructure; ReWalk's expectations as to its clinical research program
          and clinical results; ReWalk's expectations regarding future growth, including its ability to increase sales in its existing geographic markets and expand to new markets; ReWalk's ability to obtain certain components of its products from
          third-party suppliers and its continued access to its product manufacturers; ReWalk's ability to repay its secured indebtedness; ReWalk's ability to improve its products and develop new products; ReWalk's compliance with medical device reporting
          regulations to report adverse events involving the Company's products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on ReWalk's ability to
          market and sell its products; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's expectations as to the results of, and the&#160;Food and Drug Administration's&#160;potential regulatory developments with respect to its mandatory 522 postmarket surveillance study; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property
          rights of others; the risk of a cybersecurity attack or breach of the Company's IT systems significantly disrupting its business operations; the impact of substantial sales of the Company's shares by certain shareholders on the market price of
          the Company's ordinary shares; ReWalk's ability to use effectively the proceeds of its offerings of securities; the risk of substantial dilution resulting from the periodic issuances of ReWalk's ordinary shares; the impact of the market price of
          the Company's ordinary shares on the determination of whether it is a passive foreign investment company; and other factors discussed under the heading "Risk Factors" in ReWalk's annual report on Form 10-K for the year ended&#160;December 31,
          2019&#160;filed with the&#160;SEC&#160;and other documents subsequently filed with or furnished to the&#160;SEC. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to
          differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements,
          whether as a result of new information, future developments or otherwise.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">Investor Contact:</font><br>
        Ori Gon<br>
        Chief Financial Officer&#160;<br>
        ReWalk Robotics Ltd.<br>
        T: +972-4-9590123&#160;<br>
        E:&#160;investorrelations@rewalk.com</div>
      <div style="text-align: justify; line-height: 1.25;"> <br>
      </div>
      <div style="text-align: justify; line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    </div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
